Wellington Shields & Co. LLC Cuts Stock Position in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Wellington Shields & Co. LLC cut its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 8.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 2,113 shares of the company’s stock after selling 200 shares during the period. Wellington Shields & Co. LLC’s holdings in GE HealthCare Technologies were worth $165,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Cathy Pareto & Associates Inc. bought a new stake in GE HealthCare Technologies in the fourth quarter worth $670,000. LMR Partners LLP bought a new stake in GE HealthCare Technologies in the third quarter worth $7,387,000. Principal Financial Group Inc. lifted its position in GE HealthCare Technologies by 1.9% in the third quarter. Principal Financial Group Inc. now owns 1,009,910 shares of the company’s stock worth $94,780,000 after buying an additional 19,010 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in GE HealthCare Technologies in the third quarter worth $1,396,000. Finally, Everence Capital Management Inc. lifted its position in GE HealthCare Technologies by 118.2% in the fourth quarter. Everence Capital Management Inc. now owns 18,870 shares of the company’s stock worth $1,475,000 after buying an additional 10,220 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

GE HealthCare Technologies Stock Performance

GEHC stock opened at $81.97 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 0.83. The business has a 50-day moving average price of $87.26 and a 200 day moving average price of $86.10. The company has a market capitalization of $37.48 billion, a P/E ratio of 18.93, a PEG ratio of 3.19 and a beta of 1.13. GE HealthCare Technologies Inc. has a 1-year low of $74.51 and a 1-year high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.19. The firm had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.33 billion. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. As a group, equities research analysts forecast that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on GEHC. Citigroup raised their price target on GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Wells Fargo & Company lifted their target price on GE HealthCare Technologies from $96.00 to $103.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Jefferies Financial Group upgraded GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their target price for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. Finally, The Goldman Sachs Group upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $85.00 to $100.00 in a research report on Tuesday. One analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, GE HealthCare Technologies currently has a consensus rating of “Moderate Buy” and an average price target of $98.75.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.